OIC Phase 2b Study – Bowel Movement Frequency and Bristol Stool Scores
Oct. 23, 2012
TD-1211 Demonstrates Improvement in Bowel Movement Frequency and Bristol Stool Scores in a Phase 2b Study of Patients with Opioid-Induced Constipation (OIC)
TD-1211 for Opioid-Induced Constipation:
Theravance-discovered, multivalent, µ-opioid receptor neutral antagonist
Peripherally selective
Designed to normalize bowel movement frequency and quality
Once daily oral dosing
